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ABSTRACT: Hypoxia is present in most solid tumors and is clinically
correlated with increased metastasis and poor patient survival. While studies
have demonstrated the role of hypoxia and hypoxia-regulated proteins in
cancer progression, no attempts have been made to identify hypoxia-
regulated proteins using quantitative proteomics combined with MALDI-
mass spectrometry imaging (MALDI-MSI). Here we present a compre-
hensive hypoxic proteome study and are the ﬁrst to investigate changes in
situ using tumor samples. In vitro quantitative mass spectrometry analysis of
the hypoxic proteome was performed on breast cancer cells using stable
isotope labeling with amino acids in cell culture (SILAC). MS analyses were
performed on laser-capture microdissected samples isolated from normoxic
and hypoxic regions from tumors derived from the same cells used in vitro.
MALDI-MSI was used in combination to investigate hypoxia-regulated
protein localization within tumor sections. Here we identiﬁed more than 100 proteins, both novel and previously reported, that were
associated with hypoxia. Several proteins were localized in hypoxic regions, as identiﬁed by MALDI-MSI. Visualization and data
extrapolation methods for the in vitro SILAC data were also developed, and computational mapping of MALDI-MSI data to IHC
results was applied for data validation. The results and limitations of the methodologies described are discussed.
KEYWORDS: hypoxia, mass spectrometry imaging, proteomics
■ INTRODUCTION
Hypoxia arises when solid tumors outgrow their blood supplies
and additionally develop abnormal vasculature systems.1 This
results in localized regions in the tumor with poor delivery of
oxygen and lack of nutrients. Hypoxia has been shown to be
clinically correlated with metastasis, treatment failure, and
decreased cancer patient survival.2 Studies have reported the
increased invasiveness ability and metastatic potential of
hypoxic tumor cells,3 and it has long been known that hypoxia
tumor cells are resistant to radiotherapy and many forms of
chemotherapy.4 Understanding protein changes that mediate
metastatic progression and drug resistance is of great interest
for understanding disease progression and improving ther-
apeutic eﬃcacy.4b Such aims require powerful and robust tools
as well as technologies that can provide insight into the
molecular organization of the tumor microenvironment, such as
to localize and identify proteins as well as to study protein−
protein interactions.
MALDI-MSI is rapidly becoming a powerful technology for
studying the distribution as well as the in situ identiﬁcation of
several classes of compounds directly within biological tissue
sections with no requirement of predeﬁned targets.5 It is
therefore possible to visualize the distribution of multiple key
molecules and investigate their relationship with the tumor
microenvironment or with drugs administered.6 It hence
creates new translational opportunities in cancer research and
provides large and heterogeneous data sets for the study of
potential cellular and molecular networks present within tumor
tissue sections, enabling in-depth studies of the tumor micro-
environment.7 In brief, tissue sections are uniformly coated
with a matrix prior to data acquisition. In most cases, the image
acquisition is performed by irradiating the sample under a
stationary laser at a spatial resolution predeﬁned by the
operator and the instrument capacities. The recorded mass
spectra are then processed together using imaging software, and
ion density maps are generated by plotting the x and y co-
ordinates against the relative abundance or intensity of a given
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analyte within the tissue section. Several studies have reported
MALDI-MSI as a huge potential for translational research
technology for cancer biomarker discovery.4b,8 Development
strategies including sample preparation methodologies plus
instrumental development have been reported and demon-
strated improvement in MALDI-MSI techniques.
The use of MALDI-MSI has been found to be powerful for
the direct analysis of in situ digested proteins within both
frozen and formalin-ﬁxed paraﬃn embedded (FFPE) tissue
sections, leading to the in situ identiﬁcation of several proteins
within the tissue sections.9 Although MALDI-MSI is a powerful
technology for the study of the localization of several bio-
molecule classes directly within tissue sections, its quantitative
nature is still limited.
While several studies have reported the strong association
of hypoxia and metastasis, none have performed quantitative
proteomic studies of hypoxia-regulated proteins and combined
this type of data with MALDI-MSI. Here we present a com-
prehensive quantitative proteomic study combined with
MALDI-MSI to identify hypoxia-regulated proteins both in
vitro and in situ. Quantitative methodologies were developed
via the stable isotope labeling with amino acid in cell culture
(SILAC). SILAC-labeled breast cancer cells were grown under
normoxic and hypoxic conditions and analyzed with mass
spectrometric identiﬁcation and relative quantiﬁcation of the
identiﬁed peptides. LC−MS/MS analyses were also conducted
on regions of normoxia and hypoxia of breast cancer tumors
grown from the same cells used in vitro isolated by laser capture
microdissection (LCM). Together, this allowed the identi-
ﬁcation of over a thousand proteins, including more than 100
unique hypoxia-regulated proteins. MALDI-MSI allowed the
localization and further identiﬁcation/validation of hypoxia-
regulated proteins at primary tumor sites. The results and
limitations of the methodologies used here are discussed.
■ MATERIAL AND METHODS
Stable Isotope Labeling of Proteins of 4T1breast Cancer
Cells
Dialyzed FBS and penicillin/streptomycin were obtained from
GibcoBRL/Invitrogen. Dulbecco’s modiﬁed Eagle’s medium
(DMEM) was obtained from Caisson lab, and ‘heavy’ and ‘light’
arginine (R10, R0) and lysine (K8, K0) were obtained from
Sigma. Metastatic mouse mammary cancer 4T1 cells (a kind
gift from Fred Miller 10) underwent SILAC according to a
protocol previously described by Jørgensen et al.11 In brief,
SILAC media were prepared with 10% dialyzed FBS, penicillin/
streptomycin and 50 mg/L of arginine and lysine. Cells were
cultured at 37 °C under normoxic conditions (5% CO2 and
20% O2) for at least 10 passages to ensure complete protein
labeling. Labeling eﬃcacy was determined prior to experimental
procedures to ensure cells were at least 95% labeled. Cells were
plated onto 8.5 cm2 tissue culture dishes (Invitrogen) and
grown to ∼60% conﬂuency before hypoxic or normoxic treat-
ment for 24 h.
2.2. In Vitro Hypoxic Conditions
For hypoxic treatment, the 4T1 mammary cancer cells were
placed into a Hypoxystation (Don Whitley Scientiﬁcs) and
incubated at 37 °C with 5% CO2 and 1% O2. The hypoxic
treatment was carried out for 24 h.
Protein Extraction and In-Gel Digestion
Following incubation, hypoxic and normoxic cells were washed
with ice-cold TBS and lysed with urea buﬀer (8 M urea,
100 mM Tris-HCl pH 8, Sigma-Aldrich, Dorset, U.K.). Protein
concentrations were determined via bicinchoninic assay (BCA)
(BCA Protein Assay kit, Thermo Fisher Scientiﬁc). A small
aliquot of each sample was kept to check for full incorporation
of labeled amino acids, and the remaining lysates were mixed in
a one-to-one ratio. Thirty μg of the mixture was run on 10%
SDS-PAGE (NuPAGE, Invitrogen) at 190 V for 1 h The gel
was then stained with InstantBlue (Expedeon), and 10 gel
bands were excised.
The gel pieces were washed sequentially with 50 mM
triethylamine bicarbonate (TEAB) buﬀer (Sigma-Aldrich) and
dehydrated in ACN (Sigma-Aldrich) until they were completely
destained. In-gel protein reduction and alkylation were carried
out using 2 mM tris(2-carboxyethyl)phosphine hydro-
chloride (Sigma-Aldrich) at 55 °C for 30 min and 55 mM
iodoacetamide (Sigma-Aldrich) at room temperature for
30 min, respectively. Tryptic digestion was performed at 37 °C
for 16 h using 20 μg/mL of trypsin (Promega, Southampton,
U.K.) contained in 50 mM TEAB buﬀer. The extract digest
solutions were transferred to clean vials, dried in a speedvac
(Thermo SAVANT SC250 Exp SpeedVac Concentrator), and
stored at −80 °C until LC−MS/MS analysis.
Tumor Samples
All animal procedures and handling was approved by the U.K.
Home Oﬃce (PPL 6796) and performed following UKCCCR
Guidelines for the Welfare and use of animals in cancer
research.12 4T1 mammary cancer cells were resuspended in
PBS prior to injection. One × 105 cells were injected into the
fourth mammary fat pad of Balb/c mice (Harlan Laboratories).
Three mice were used for this study. Mice were monitored and
culled when tumors reached the maximum allowed size (about
4 weeks after tumor cell injection). For this study, ﬁve tumor
samples were collected and used. One hour prior to sacriﬁce,
mice were injected intraperitoneally with 100 μL of
pimonidazole hydrochloride (pimo) (hydroxyprobe-1; NPI,
Belmont, MA) at 60 mg/kg. Tumour tissue samples were
harvested and immediately treated with a Stabilizor system
(Denator AB, Sweden) according to the supplier instructions.
This treatment aimed to inhibit enzymatic activity within the
tissue sample. The tumor tissue samples were ﬁxed in 4%
buﬀered formalin and embedded in paraﬃn. Alternatively,
tumors were snap-frozen in liquid nitrogen and stored
at −80 °C until further analysis. Five μm sections were cut
using either a cryostat (Leica Microsystems, U.K.) or cryotome
(Leica Microsystems, U.K.) and mounted onto indium tin
oxide (ITO) (Sigma-Aldrich) or histological glass slides
(Menzel-Glaser, Germany). Formalin-ﬁxed paraﬃn-embedded
(FFPE) tissue sections were stored at room temperature until
further analysis.
Laser Capture Microdissection, Protein Extraction and
Digestion
For LCM, 5 μm frozen or FFPE tumor tissue sections were cut
using a cryostat (Leica Microsystems, U.K.) and mounted on
DIRECTOR glass slides (Expression Pathology). The tissue
sections were dehydrated and stained with hematoxylin
according to a protocol provided by Expression Pathology.
Immunohistochemical staining for hypoxia markers pimo and
CA-IX were also performed on serial tissue sections for visual
localization of hypoxic and normoxic regions. The LCM was
Journal of Proteome Research Article
dx.doi.org/10.1021/pr401056c | J. Proteome Res. 2014, 13, 2297−23132298
carried out using a LEICA LMD6000 (LEICA Microsystems).
Approximately 106 cells from hypoxic and normoxic regions
were collected into eppendorf caps. In solution protein
reduction, alkylation and tryptic digestion were performed
according to the Expression Pathology protocol. The peptides
were desalted and puriﬁed using C-18 stage tip (3 M Empore)
and then dried in a speedvac (Thermo SAVANT SC250
Exp SpeedVac Concentrator) and stored at −80 °C until
LC−MS/MS analysis.
Tissue Preparation for MALDI-MSI
Prior to trypsin and matrix deposition, FFPE tumor tissue
sections were prepared as previously described.12 In brief,
paraﬃn ﬁlm was removed using xylene; then, the tissue sections
were rehydrated in a series of ethanol solutions. Antigen
retrieval was performed in AR buﬀer (DAKO) in a water bath
for 15 min at 90 °C. The sections were cooled to room
temperature, rinsed with water, and then allowed to dry at
room temperature before trypsin and matrix deposition.
Trypsin and matrix depositions were achieved using the
ImagePrep station (Bruker Daltonik, Bremen, Germany). A
trypsin solution was prepared at 20 μg/mL in 50 mM
ammonium bicarbonate buﬀer (pH 8.1) containing 0.1%
octyl glucoside.13 Using the ImagePrep station, 400 μL of
trypsin solution was sprayed onto the tissue section over
60 spraying cycles, thus ensuring that the tissue section is not
over wetted. The tissue section was then incubated for 2 h at
37 °C (5% CO2) in a humid environment. Alpha-cyano-4-
hydrocinnamic acid (Sigma-Aldrich), mixed with aniline
(Sigma-Aldrich), was used as matrix.13,14 The matrix solution
was prepared at 7 mg/mL in 60% ACN and 0.1% TFA and
deposited onto the tissue sections using the ImagePrep station.
NanoLC−MS/MS Analyses and Database Searching
Trypsin-digested peptides from both LCM and in-gel digestion
were subjected to LC−MS/MS using the NanoLC-Ultra 2D
chromatography system (Eksigent, Dublin, Ireland) coupled to
an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher
Scientiﬁc, Hemel Hempstead, U.K.). Reversed-phase chromato-
graphic separation was carried out on a 50 μm inner diameter ×
100 mm C18 ReproSil-Pur column (3 μm particle size; Dr
Maisch HPLC, Germany) over a 40 min linear gradient of 5−
40% solvent B (solvent A: 0.1% formic acid; solvent B: ACN
100%, 0.1% formic acid). The mass spectrometer was operated
in the data-dependent mode to automatically switch between
Orbitrap MS and ion trap MS/MS acquisition. Survey full-scan
MS spectra (from m/z 375−2000) were acquired in the
Orbitrap with a resolution of 60 000 at m/z 400 and FT target
value of 1 × 106 ions. The 20 most abundant ions were selected
for CID and dynamically excluded for 8 s. For accurate mass
measurement, the lock mass option was enabled using the
polydimethylcyclosiloxane ion (m/z 455.120025) as an internal
calibrant.
For protein identiﬁcation from LCM samples, raw MS/MS
data were submitted for database searching using Proteome
Discoverer v1.3 and Mascot v2.2. and searched against
SwissProt version 57.14 (514 789 sequences) mammalian
(64 919 entries) and Mus musculus (16 22 entries). The
following Mascot search parameters were used: peptide
tolerance, 10 ppm; fragment tolerance, 0.6 Da; trypsin missed
cleavage, 2; variable modiﬁcations, acetyl (Protein N-term)
carbamidomethyl (C), oxidation of methionine, PyroGlu
(Peptide N-term Q). MS/MS-based peptide and protein
identiﬁcations were grouped and validated using Scaﬀold v3.0
(Proteome Software, Portland, OR). Protein identiﬁcations
were automatically accepted if they contained at least two
unique peptides assigned with at least 95% conﬁdence by
Peptide Prophet1, in accordance with guidelines from Journal of
Proteome Research.
For peptide identiﬁcation from in-gel digested samples, raw
MS/MS data ﬁles were submitted for database searching using
Proteome Discoverer v1.3 and Mascot v2.2 and searched
against Swiss-Prot (Sprot_Mouse_20110414.fasta, v14-3-3) as
well as Ensembl (EN_mmusR53_.fasta, version EC 1.6.5.3).
Another database was used to facilitate the STRING Network
analysis. The following MASCOT search parameters were used:
peptide tolerance, 100 ppm; fragment tolerance, 0.6 Da; trypsin
missed cleavage, 2; variable modiﬁcations, acetyl (protein
N-term) carbamidomethyl (C), oxidation of methionine,
PyroGlu (Peptide N-term Q). For MS/MS-derived in vitro
SILAC data, the following modiﬁcations were added: SILAC
Lys (13C6
15N2) SILAC Arg (
13C6
15N4).
MALDI-MSI and MALDI-MS/MS Analyses
MALDI-MSI analyses were acquired directly from the in situ
digested tumor sections over a mass range m/z 800 to 2500 in
reﬂector positive mode using a 4800 Plus MALDI TOF/TOF
analyzer (Applied Biosystems/MDS Sciex, Concord, Canada)
operating with a 200 Hz Nd:YAG laser. The instrument calibra-
tion was performed using a solution of peptide standards (4700
Proteomics analyzer calibration mixture, Applied Biosystems/
MDS Sciex) ranging between m/z 900 and 4000 prior to
MALDI-MSI analysis. Peptide images were acquired at a spatial
resolution set at 80 μm with 250 laser shots per position,
and ion images were generated with TissueView 1.0 software
(Applied Biosystems/MDS Sciex), which can be used to
measure the amplitude of selected mass signals and to
reconstruct 2D ion density maps.
MALDI-MS/MS analyses were performed directly from the
in situ digested tumor tissue sections. Using the control soft-
ware, the tissue section areas were subdivided into small
partitions to mimic an LC−MALDI plate across the tissue
sections. MS data were acquired at 200 Hz with 200 laser
shots/spec. Subspectra were acquired every 50 shots.
Automatic MS/MS data were acquired at 200 Hz in 1 kV
MS/MS mode with 2000 laser shots/spectrum on the top three
precursors. For peptide identiﬁcation from on-tissue digested
tissues, MS/MS peak lists were submitted for database
searching using Mascot v2.2 and searched against Swiss-Prot
(Sprot_Mouse_20110414.fasta, v14-3-3) as well as Ensembl
(EN_mmusR53_.fasta, version EC 1.6.5.3). The following
MASCOT search parameters were used: peptide tolerance,
100 ppm; fragment tolerance, 0.6 Da; trypsin missed cleavage, 2;
variable modiﬁcations, acetyl (protein N-term) carbamidomethyl
(C), oxidation of methionine, PyroGlu (peptide N-term Q).
Network Analysis Using PANTHER and STRING
Data sets obtained from SILAC in vitro quantitative studies,
which contained hypoxia-regulated proteins, were classiﬁed
according to biological process using the PANTHER platform
(available from www.pantherdb.org).
In addition to PANTHER analysis, the SILAC data sets were
analyzed using STRING database version 9.0.15 The STRING
database was queried about the associations of all MS-detected
proteins with a combined conﬁdence score of at least 0.8. The
pipeline is implemented by several computer programs
implemented in Perl (Perl version 5.14.2) and Bash (GNU
Bash version 4.0.33) scripts. It is fully automated, ensuring that
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the results are completely reproducible and free of bias. In brief,
the pipeline was constructed as follows: conversion of the MS
results spreadsheet into text ﬁles; creation of a mapping
between Ensembl and HUGO protein identiﬁcation by
enquiring Biomart (http://www.biomart.org); and, if required,
STRING using its web API (http://string-db.org/help/index.
jsp?topic=/org.string-db.docs/api.html). The purpose of this is
to use Ensembl identiﬁcation for STRING queries and HUGO
gene symbols for generating protein interaction networks with
readily understandable protein names; MS-detected proteins
were then grouped according to signiﬁcance (signiﬁcance
deﬁned as >1.4 fold change between hypoxia and normoxia);
STRING was queried about interactions between the proteins,
and the interactions without a high enough STRING score
were ﬁltered out; a graph was constructed where the nodes are
the signiﬁcant proteins and the edges are the interactions as
returned by STRING; two lists were generated for each node in
the graph, one of its immediate neighbors with signiﬁcant up-
regulation and one of its immediate neighbors with signiﬁcant
down-regulation, allowing data extrapolation for ease of
analysis; and statistics of the resulting graph such as degree
distribution, clustering coeﬃcient, and so on were calculated.
These can be used to programmatically identify hubs, networks,
and proteins bridging the networks and correlate these results
with fold changes in protein expression.
The ﬁnal step in the pipeline is to convert the graph into
Cytoscape 2.816 data and respective property ﬁles for
interactive visualization using the following conventions:
1) Each node represents a protein detected by MS. Note:
kinases are depicted as squares to distinguish from other
types of proteins.
2) The color of each node represents various properties of
the protein detected:
a. Red: up-regulated in hypoxia. Intensity of color
correlates with increase in up-regulation.
b. Blue: down-regulated in hypoxia. Intensity of color
correlates with increase in down-regulation.
c. White: no signiﬁcant changes between the two
conditions.
3) The size of each node represents its degree; the degree is
deﬁned as the number of associations the protein has.
4) Proteins with no interactions satisfying the speciﬁed
minimum STRING score are removed from the resulting
ﬁgure.
Validation of Hypoxia-Associated Proteins Using Statistical
Analysis of MALDI-MSI Data
The detailed methodology used here can be found in the
Supporting Information (Method S1). In brief, MALDI-MSI
scans were subjected to spectral processing including baseline
correction, peak identiﬁcation, and peak alignment prior to
statistical analysis. For statistical analyses, MALDI-MS images
were coregistered with IHC stained images. An example of
coregistered image is shown in Figure S1 in the Supporting
Information. Aligned MS peaks were extracted from hypoxia
and normoxia regions, localized by IHC staining images, and
tested for equal mean intensity using a t test.
Immunoﬂuorescence (IF) Staining of Pimonidazole on
Frozen Pimo-Treated Tumor Tissue Sections
4T1 frozen pimo-treated tumor tissue sections were dried at
room temperature for 30 min and then ﬁxed in ice-cold acetone
for 30 min. Tissue sections were allowed to dry at room
temperature for 20 min, and an ImmEdge pen (H-4000, Vector
Laboratories, Peterborough, U.K.) was used to encircle the
sections, prior to incubation in 1%BSA/PBS for 30 min at room
temperature. Sections were incubated with hydroxyprobe
antipimo MAB-1 antibody (NPI, Belmont, MA) at a dilution
of 1:100 in IF buﬀer for 1 h at room temperature in the dark.
Control slides were incubated with just IF buﬀer during this
period of time. This was followed by three washes with 300 μL
of PBS for 5 min each and then incubation with Goat
antimouse AlexaFluor488 (Invitrogen) at 1:1000 dilution in IF
buﬀer for 1 h at room temperature in the dark, followed by
three washes with 300 μL of PBS for 5 min each. The sections
were then counter-stained with 200 μL of 4′,6-diamidino-2-
phenylindole (DAPI; D21490, Invitrogen,) at a dilution of
1:1000 in PBS. Slides were rinsed in PBS and mounted in
Vectashield (H-1000, Vector Laboratories). The stained images
were visualized using an Olympus BX51 research microscope
(Olympus U.K., Southend-on-Sea, U.K.) with a DP72 camera
(Olympus U.K.) operating in ﬂuorescence mode and using
CellD (Olympus U.K.) software.
Immunohistochemistry (IHC) Staining on FFPE Tumor
Tissue Sections
Paraﬃn was removed from FFPE tumor tissue sections (5 μm
thickness) by immersing the slides twice in 100% xylene
(Sigma-Aldrich) at room temperature for 10 min each, followed
by a rehydration of the tissue sections through a series of
ethanol solutions of increasing water concentrations (100, 85,
and 70%; vol/vol in water, 10 min each) before a ﬁnal 5 min of
incubation in water. Residual endogenous peroxidase activity
was blocked by incubating the sections in 3% hydrogen
peroxide in methanol for 15 min at room temperature. Antigen
retrieval was carried out in a target retrieval citrate buﬀer (pH
6.0) (DAKO UK, Cambridgeshire, U.K.) at 95 °C for 15 min.
Sections were allowed to cool to room temperature, rinsed with
PBS, and then incubated in PBS/5% goat blocking serum
(Invitrogen) for 1 h at room temperature to minimize
nonspeciﬁc binding. Sections were incubated with the following
primary antibodies: hydroxyprobe antipimo MAB-1 antibody
(NPI, Belmont, MA) at 1:100 dilution in PBS/1% goat serum
at room temperature for overnight. As negative staining con-
trols, separate tissue section slides were incubated in PBS/1%
goat serum without primary antibodies. After washing with
PBS, tumor tissue sections were then incubated with
streptavidin−biotin peroxidase solution at 1:500 dilution
(Vector Laboratories, Burlingame, CA) at room temperature
for 30 min. Visualization of antibody binding on the sections
was performed using 3,3′-diaminobenzidine (BioGenex Labo-
ratories, San Ramon, CA), and tissue sections were counter-
stained with Mayer’s hematoxylin (Sigma Aldrich) for 60 s
before being dehydrated and coverslipped. The images of the
IHC staining were taken on an Olympus BX51 research
microscope (Olympus U.K.) with a DP72 camera (Olympus
U.K.) operating in brightﬁeld mode using CellD (Olympus
U.K.) software.
■ RESULTS
Quantitative Proteomic Analysis of Hypoxia-Associated
Proteins in Vitro
Because hypoxia is prominent in solid tumors such as breast
cancer and it was previously demonstrated that the HIF1α
levels have a positive correlation with pathologic stage,17 we
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decided to focus our investigation on hypoxia-associated
proteins in a breast cancer model.
To perform a quantitative study of the proteomic changes
that occur in normoxic versus hypoxic breast cancer cells, we
ﬁrst used 4T1 mouse mammary cancer cells in vitro. These cells
were chosen as we have previously shown that hypoxia drives
metastasis of 4T1 cells.18 The cells were grown independently
in either the presence of ‘light’ arginine and lysine (R0K0) or
‘heavy’ arginine and lysine (R10K8) SILAC media. The R0K0
cells were subjected to 24 h of hypoxic treatment (1% O2), and
the R10K8 cells were subjected to 24 h normoxic treatment
(20% O2). Figure 1A shows the experimental workﬂow for
Figure 1. Experimental workﬂow for LC−MS/MS analysis of SILAC-labeled 4T1 breast cancer cells. (A) 4T1 mouse mammary cancer cells were
incubated for 24 h in normoxia and hypoxia. Hypoxic cells were labeled with light arginine and lysine (R0K0) and normoxic cells were labeled with
heavy arginine and lysine (R10K8). Cell populations were mixed in 1:1 ratio, and extracted proteins were separated on SDS-PAGE. Following in-gel
digestion, peptides were isolated and puriﬁed prior to LC−MS/MS analysis on LTQ-Velos Orbitrap. (B) Digital scan of SDS-PAGE separation of
protein extracts. (C) SILAC peptide pairs were relatively quantiﬁed for both hypoxic and normoxic conditions.
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LC−MS/MS analysis of SILAC-labeled 4T1 mammary cancer
cells. Proteins extracted from these two sets of cells were mixed
1:1 ratio, followed by SDS-PAGE separation. Figure 1B shows
the digital scan of SDS-PAGE separation of the protein extracts
from both individual and mixed 1:1 cell populations. After in-
gel digestion of the extracted proteins, analyses were conducted
on the resulting peptides using LC−MS/MS (Figure 1C). It
was conﬁrmed that the labeled amino acids were incorporated
97.9% into the 4T1 cells (data not shown).
Because the SILAC labeling methodology results in mass
diﬀerences between peptides with similar sequences, it is
possible to determine the relative abundance of each peptide
and perform a quantitative comparison based on their extracted
ion current (Figure 1C). Here LC−MS/MS analyses were
repeated on three independent sets of SILAC-labeled 4T1 cells.
In total, 1416 proteins were identiﬁed, 268 proteins were
detected in all repeats, and 131 proteins were consistently up-
or down-regulated in all repeats. The complete protein list can
be found in the Table S1 in the Supporting Information. 60
proteins were found to be consistently up-regulated under
hypoxic conditions, including glyceraldehyde-3-phosphate
dehydrogenase, L-lactate dehydrogenase A chain, and phos-
phoglycerate kinase. 71 proteins were found to be consistently
down-regulated under hypoxic conditions. These included
ribosomal proteins and ubiquitin-associated proteins. Table 1
shows a list of the most signiﬁcant proteins found to be up- or
down-regulated in hypoxic versus normoxic conditions
(signiﬁcance deﬁned as >1.4 fold change between hypoxia
and normoxia). Figure 2A shows the top up- or down-regulated
proteins (based on fold change) in hypoxic versus normoxic
conditions. The top 40 up- or down-regulated proteins were
classiﬁed according to biological process and molecular
functions using PANTHER. Figure 2B shows the functional
classiﬁcation of the proteins that were found consistently up- or
down-regulated under hypoxic conditions. It can be noted that
both up- and down-regulated hypoxia-associated proteins are
Table 1. List of Identiﬁed Signiﬁcant Hypoxia-Regulated Proteins after LC−MS/MS Analysis of 4T1 SILAC-Labelled Mammary
Cancer Cellsa
Top 16 up-regulated proteins under hypoxic conditions
accession description A2: heavy/light B2: heavy/light C2: heavy/light average heavy/light
E9QLP8 keratin, type I cytoskeletal 10 0.223 0.062 0.057 0.114
P05064 fructose-bisphosphate aldolase A 0.603 0.463 0.332 0.466
P12382 6-phosphofructokinase, liver type 0.601 0.411 0.405 0.472
P17751 triosephosphate isomerase 0.573 0.476 0.384 0.478
P09411 phosphoglycerate kinase 1 0.656 0.443 0.359 0.486
Q9DBJ1 phosphoglycerate mutase 1 0.596 0.537 0.433 0.522
P06151 L-lactate dehydrogenase A chain 0.705 0.557 0.394 0.552
Q6IRU2 tropomyosin alpha-4 chain 0.484 0.835 0.517 0.612
F6TS28 galectin-3 0.655 0.528 0.659 0.614
P16858 glyceraldehyde-3-phosphate dehydrogenase 0.777 0.59 0.489 0.619
P35700 peroxiredoxin-1 0.438 0.78 0.709 0.642
P17182 alpha-enolase 0.812 0.666 0.512 0.663
P16045 galectin-1 0.53 0.753 0.732 0.672
P07356 annexin A2 0.846 0.518 0.682 0.682
Q6ZQ38 cullin-associated NEDD8-dissociated protein 1 0.796 0.743 0.537 0.692
P97429 annexin A4 0.894 0.573 0.621 0.696
Top 16 down-regulated proteins under hypoxic conditions
accession description A2: heavy/light B2: heavy/light C2: heavy/light average heavy/light
Q5SWU9 acetyl-CoA carboxylase 1 1.587 1.547 1.26 1.465
P46935 E3 ubiquitin-protein ligase NEDD4 1.763 1.221 1.443 1.476
Q61656 probable ATP-dependent RNA helicase DDX5 1.544 1.292 1.645 1.494
F8WIE5 E3 ubiquitin-protein ligase HECTD1 1.637 1.554 1.295 1.495
Q9ERU9 E3 SUMO-protein ligase RanBP2 1.836 1.475 1.201 1.504
Q7TMY8-3 isoform 3 of E3 ubiquitin-protein ligase HUWE1 2.172 1.355 1.041 1.523
E9QKG6 ankyrin repeat domain-containing protein 17 1.591 1.66 1.439 1.563
Q7TMB8-2 isoform 2 of cytoplasmic FMR1-interacting protein 1 2.282 1.285 1.176 1.581
Q8VDJ3 vigilin 2.026 1.498 1.376 1.633
Q9DCV7 keratin, type II cytoskeletal 7 2.755 1.119 1.079 1.651
H3BJU7 rho guanine nucleotide exchange factor 2 2.625 1.027 1.354 1.669
Q80U93 nuclear pore complex protein Nup214 2.379 1.782 1.21 1.79
Q80TP3 E3 ubiquitin-protein ligase UBR5 2.418 2.012 1.118 1.849
P67778 prohibitin 0.941 0.893 3.935 1.923
P10854 histone H2B type 1-M 1.709 1.211 3.76 2.227
Q5XG71 small subunit processome component 20 homologue 6.601 1.68 3.08 3.787
a4T1 mammary cancer cells were treated under normoxia and hypoxia conditions. Hypoxic cells were labelled with light arginine and lysine (R0K0)
and normoxic cells were labelled with heavy arginine and lysine (R10K8). The samples were mixed 1:1 ratio and ran on SDS-PAGE followed by in-
gel digestion and LC−MS/MS analysis. Proteome Discoverer v1.3 and Mascot v2.2 were used to analyze the raw data ﬁles. A heavy/light ratio was
calculated for each identiﬁed protein by the software. Signiﬁcance was deﬁned as at least 1.4-fold change in protein expression between the two
conditions.
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Figure 2. In vitro SILAC-LC−MS/MS quantiﬁcation of proteins diﬀerentially regulated in hypoxia and normoxia in 4T1 cells. (A) Fold changes of
regulated proteins in vitro in hypoxia versus normoxia. For quantitative analysis of the diﬀerences observed between peptide paired, a 1.4-fold cut oﬀ
was applied. The top 40 up- and down-regulated hypoxia-associated proteins are displayed. The up-regulated proteins present in hypoxic regions are
shown from the left and the down-regulated proteins in hypoxic regions are displayed from the right, with the fold-change displayed on top of the
bars. (B) PANTHER classiﬁcation of up and down-regulated hypoxia-associated proteins in vitro. Results from in vitro protein quantitation of 4T1
SILAC-labeled cells were analyzed using PANTHER software. Signiﬁcantly up- and down-regulated hypoxia-associated proteins detected were
classiﬁed according to (b1, b3) biological process, and (b2, b4) molecular function.
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mainly involved in biological processes like metabolic processes
(e.g., up-regulation in protein and carbohydrate metabolic pro-
cesses, down-regulation in protein and nucleobase/nucleoside/
nucleotide/nucleic acid metabolic processes) and cellular
processes (e.g., up-regulation in cell communication, cell
motion and reorganization of cellular components, down-
regulation in cellular component organization, cell cycle, cell
adhesion, and cell communication), whereas the molecular
functions of the proteins detected are mainly involved in
binding (e.g., protein and nucleic acid binding in both cases,
up-regulation in calcium ion and calcium-dependent phosphor-
lipid binding) and catalytic activities (e.g., up-regulation in
oxidoreductase, transferase, hydrolase and isomerase activity,
down-regulation in ligase, hydrolase and transferase activity).
Identiﬁcation of Hypoxia-Associated Proteins in Situ Using
LCM LC−MS/MS
Protein expression changes were also studied in situ using tissue
samples isolated from frozen 4T1 tumor tissue sections.
Regions of normoxia and hypoxia of orthotopic mammary
tumors, grown from the same 4T1 cells as used in vitro, were
isolated by laser microdissection (LCM). Pimonidazole (pimo),
which is a small molecule used clinically to localize regions of
hypoxia within tumor tissues,19 was used to locate hypoxic
regions in our 4T1 tumor sections by IF (Figure 3). This
allowed the visual localization of hypoxic and normoxic regions
prior to LCM. The captured cells from each region of
microdissected tumor tissue section were digested in solution
and submitted to LC−MS/MS analysis. Following LC−MS/MS,
118 mouse proteins were identiﬁed within the normoxic LCM
tissue sample, and 164 mouse proteins were identiﬁed within the
hypoxic LCM tissue sample.
Tables S2 and S3 list the proteins identiﬁed in hypoxic
regions and normoxic regions, respectively, and are given in the
Supporting Information. The most readily detected proteins in
the hypoxic regions were from a wide range of protein families
including structural proteins (actins, myosins, collagens) and
nuclear and translational proteins (histones, ribosomal proteins,
elongation factors). When comparing both data sets obtained
from LCM-LC−MS/MS analyses of hypoxic and normoxic
regions, 89 proteins were found to be present in both hypoxic
and normoxic regions, presenting either similar or diﬀerent
intensities. 75 proteins were detected only in hypoxic regions.
Table 2 shows a summary list of the identiﬁed proteins from
tissues isolated from in situ hypoxic regions of 4T1 primary
tumor sections after LCM-LC−MS/MS and which are
associated with hypoxia. Standard and robust hypoxia-regulated
proteins such as 78 kDa glucose-regulated protein (Grp78),
phosphoglycerate kinase, and L-lactate dehydrogenase A chain
were found to be present in hypoxic regions. Grp78 was
detected with a higher intensity in hypoxic regions compared
with normoxic regions, whereas phosphoglycerate kinase and
L-lactate dehydrogenase A chain were exclusively detected in
Figure 3. Immunoﬂuorescence staining of Pimonidazole in frozen 4T1 primary mammary tumor tissue section. IF staining of pimo localization within
frozen 4T1 pimo-treated tumor tissue sections allows us to distinguish between hypoxic and normoxic regions for subsequent LCM-LC−MS/MS
analyses. Left: pimo-immunoﬂuorescence staining, middle: DAPI counter stain of cell nuclei, right: overlay of the two staining. Scale bars = 100 μm.
Sections viewed at (A) 10× magniﬁcation and (B) 20× magniﬁcation.
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hypoxic regions of the tumor tissue sections. Additionally,
galectin-1, a well-known hypoxia-induced protein, was also
among the top 20 proteins in the list. Some proteins that have
unreported hypoxic regulation but whose functions are
associated with hypoxia response were also detected in either
hypoxic regions or both hypoxic and normoxic regions. These
include 60 kDa heat shock protein, which was found to be
exclusively present in hypoxic regions.
Comparison between in Vitro and in Situ LC−MS/MS Data
Set
Data obtained from in vitro quantitative proteomic LC−MS/
MS analyses were compared with those obtained from LCM-
LC−MS/MS analyses (see Supporting Information Table S4).
Among the top 131 proteins found to be up- or down-regulated
under hypoxic conditions following SILAC LC−MS/MS,
38 proteins were identiﬁed and found to be present in hypoxic
or normoxic regions following LCM-LC−MS/MS. Twenty-six
proteins were found to be common between up-regulated
proteins under hypoxic conditions from SILAC LC−MS/MS
studies and proteins identiﬁed in LCM hypoxic regions. These
include proteins such as phosphoglycerate kinase 1, galectin,
and annexin. Figure 4 shows a diagram to visualize the common
and distinct proteins in all analysis data sets.
Localization of Hypoxia in 4T1 Primary Tumor Tissue
Sections Using MALDI-MS Imaging
FFPE pimo-treated 4T1 tumor tissue sections were subjected
to IHC staining to locate hypoxic regions. Figure 5A shows the
localization of hypoxic regions within a whole FFPE 4T1 tumor
tissue section by IHC staining for pimo. Serial sections were
then subjected to MALDI-MSI and on-tissue MS/MS analyses
to obtain molecular information and protein identiﬁcation.
Figure 5B shows a resulting average MALDI mass spectrum
acquired from one pixel across the tissue section. Direct
MS/MS results were subjected to MASCOT search, and this
allowed the identiﬁcation of 15 proteins directly from the tissue
section. This enabled the identiﬁcation of mostly abundant
proteins including hemoglobin, actin, histone, and vimentin.
Here combining both LC−MS/MS and MALDI-MSI results
enabled the localization and identiﬁcation of proteins shown in
Figure 5C. The protein localizations displayed in Figure 5C
were accepted only if at least two peptides arising from the
same protein (based on quantitative LC−MS/MS analyses
from both in vitro and LCM samples) showed a similar
Table 2. Summary List of Identiﬁed Proteins from Tissues Isolated from in Situ Hypoxic Regions of 4T1 Primary Tumour
Sections after LCM-LC−MS/MSa
1. standard and robust hypoxia-regulated proteins
accession description score coverage no. proteins peptide peak area MW [kDa] peptide peak area found in normoxia
P16045 galectin-1 16.75 23.7 1 2.09 × 108 14.9 5.03 × 108
P20029 78 kDa glucose-regulated protein 49.2 19.08 1 5.93 × 107 72.4 3.48 × 107
P06151 L-lactate dehydrogenase A chain 11.8 10.24 2 2.55 × 107 36.5 0 (hypoxia only)
P09411 phosphoglycerate kinase 1 4.31 5.52 1 7.51 × 106 44.5 0 (hypoxia only)
2. Reported hypoxic regulation
accession description score coverage # proteins peptide peak area MW [kDa] peptide peak area found in normoxia
P62204 calmodulin 40.12 30.87 2 1.36 × 108 16.8 1.08 × 108
P63101 14−3−3 protein zeta/delta 35.29 25.31 1 8.50 × 107 27.8 7.38 × 107
P48036 annexin A5 29.19 19.75 1 6.94 × 107 35.7 4.18 × 107
P48678 prelamin-A/C 89.52 24.66 1 6.66 × 107 74.2 0 (hypoxia only)
P18760 coﬁlin-1 14.08 31.93 1 6.38 × 107 18.5 0 (hypoxia only)
P62259 14−3−3 protein epsilon 33.04 25.88 1 5.78 × 107 29.2 5.44 × 107
P52480 pyruvate kinase isozymes M1/M2 25.44 10.55 2 4.20 × 107 57.8 2.79 × 107
P17182 alpha-enolase 20.48 10.14 1 3.96 × 107 47.1 0 (hypoxia only)
P05064 fructose-bisphosphate aldolase A 23.3 15.66 2 2.82 × 107 39.3 0 (hypoxia only)
P08249 malate dehydrogenase, mitochondrial 5.63 5.92 1 1.74 × 107 35.6 1.96 × 107
P14733 lamin-B1 14.77 9.35 1 1.74 × 107 66.7 0 (hypoxia only)
P62962 proﬁlin-1 6.1 17.14 1 1.35 × 107 14.9 0 (hypoxia only)
P10107 annexin A1 13.27 11.85 2 1.29 × 107 38.7 0 (hypoxia only)
O35639 annexin A3 10.65 11.76 1 1.29 × 107 36.4 5.70 × 106
H7BXC3 triosephosphate isomerase 12.35 16.77 2 7.14 × 106 18 1.24 × 107
3. unreported hypoxic regulation but function associated with hypoxia responses
accession description score coverage
#
proteins peptide peak area
MW
[kDa] peptide peak area found in normoxia
P10126 elongation factor 1-alpha 1 41.39 18.4 1 1.73 × 108 50.1 1.17 × 108
P02089 hemoglobin subunit beta-2 40.51 44.9 1 1.07 × 108 15.9 1.31 × 108
Q504P4 heat shock cognate 71 kDa protein 53.79 22.33 2 4.80 × 107 68.7 4.24 × 107
P11499 heat shock protein HSP 90-beta 45.09 17.82 1 4.55 × 107 83.2 2.44 × 107
P56480 ATP synthase subunit beta, mitochondrial 7.64 6.05 1 1.39 × 107 56.3 0 (hypoxia only)
Q03265 ATP synthase subunit alpha, mitochondrial 8.02 5.97 1 9.67 × 106 59.7 1.25 × 107
P63038 60 kDa heat shock protein, mitochondrial 5.16 3.66 1 7.45 × 106 60.9 0 (hypoxia only)
aHypoxic regions were identiﬁed by IHC staining, and LCM was performed to isolate tissues from hypoxic regions. The captured tissues were then
digested in solution and submitted to LC−MS/MS analysis. Proteome Discoverer 1.3 was used for analysis. Proteins that were found to be
associated with hypoxia are displayed. An extensive list of identiﬁed proteins can be found in the Supporting Information.
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distribution across the tissue section. Such approaches have
already been demonstrated and used by Chaurand et al.20 Using
both MALDI-MSI and quantitative LC−MS/MS, we conﬁrmed
the distribution of proteins identiﬁed within 4T1 tumor tissue
sections. Figure 5C displays the localization of peptides arising
from several proteins, including classic hypoxia markers
phosphoglycerate kinase-1 and galectin. When comparing the
MALDI-MS images with the immunostaining for regions of
hypoxia, we noted that the displayed peptides were mainly
localized to and relatively abundant in hypoxic regions. Also,
the distribution of peptides arising from hemoglobin alpha- and
beta-chain (m/z 1529 and 1274) showed the presence of blood
supply in normoxic regions adjacent to the hypoxic regions.
The results obtained by MALDI-MSI analyses enabled localiza-
tion of hypoxia-regulated proteins directly in tumor tissue
sections. These results also highlight the advantage of MALDI-
MSI over traditional IHC methods in localization of the protein
of interest, as IHC allows only one target to be detected per
sample, whereas MALDI-MSI allows a multitude of targets to
be detected in a single experiment.
Validation of Hypoxia-Associated Proteins Using Statistical
Analysis of MALDI-MSI Data
Here we developed a computational pipeline to match proteins
identiﬁed with MALDI-MSI to the hypoxic/normoxic areas
identiﬁed through IHC staining. Query proteins ﬁbronectin,
galectin, hemoglobin, heat shock protein 27, and phosphogly-
cerate kinase were tested for association with hypoxia, that is,
whether they have signiﬁcantly higher or lower expression in
hypoxic tissue compared with normoxic tissue. In Figure 6A,B,
boxplots and density distributions of peak intensities of
phosphoglycerate peptides (1083 m/z) stemming from hypoxic
(red) and normoxic (blue) areas of the section are shown.
Using the Student’s t test, the hypothesis of equal mean, that is,
same level of average expression in hypoxia and normoxia, can
be rejected in favor of the alternative hypothesis with a
signiﬁcant p value of 1.3 × 10−35. As shown in Table 3, all
tested proteins except hemoglobin A exhibit a statistically
signiﬁcant diﬀerent (p < 0.01) mean expression between
normoxic and hypoxic tissue.
Protein Network Analysis
We developed an algorithm whereby all proteins consistently
detected in all repeats of the in vitro SILAC system were
analyzed using the STRING database. We extracted the
associations of all MS-detected proteins and visualized the
resulting network using Cytoscape, with proteins that were
signiﬁcantly up- or down-regulated (deﬁned as at least 1.4-fold
change) highlighted as either red or blue nodes, respectively,
and those that exhibited no change in white (Figure 7A,B).
This enabled us to visualize the connections between the
detected proteins and build up an interaction network even
though not all proteins were signiﬁcantly altered, thereby
providing a ‘snapshot’ of the true state of the protein networks
within the cells at the time of sample collection. As can be seen
from Figure 7A, the detected proteins in 4T1 samples formed
extensive complex networks. There is one major network
containing several interconnected hubs. This observation is as
expected because proteins in cells generally interact with each
other for many purposes. Additionally, proteins with only one
connection were also detected.
In addition to visualization using Cytoscape, an algorithm
was developed to further interrogate the individual proteins
with signiﬁcant changes between hypoxia and normoxia, by
Figure 4. Venn diagram of the number of common and distinct proteins identiﬁed with SILAC LC−MS/MS, LCM LC−MS/MS, and MALDI-MSI.
(A) Comparison between the observed top 60 up-regulated proteins following SILAC LC−MS/MS analysis with those identiﬁed after LCM LC−
MS/MS analysis of 4T1 pimo-treated tumor tissue sections. (B) Comparison between the observed top 71 down-regulated proteins following
SILAC LC−MS/MS analysis with those identiﬁed after LCM LC−MS/MS analysis of 4T1 pimo-treated tumor tissue sections. (C) Comparison
between the number of successfully identiﬁed proteins using SILAC LC−MS/MS, LCM LC−MS/MS and MALDI-MSI analyses.
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identifying signiﬁcantly altered proteins that are neighbors with
another signiﬁcantly altered protein (Table 4). The Table was
subdivided into four parts according to the detected hypoxia
levels assigned to each protein, with “up” (i.e., fold-change of
heavy label (normoxia) /light label (hypoxia) < 0.714) meaning
the protein was up-regulated in hypoxia, and “down” (i.e., fold-
change of heavy label (normoxia)/light label (hypoxia) > 1.4)
meaning the protein was down-regulated in hypoxia: up−up,
up−down, down-up, and down−down. This allows us to extrapolate
information on potential protein regulators from the extensive
network. For example, the protein Tpr was detected to be
down-regulated in hypoxia, and its neighboring proteins were
also down-regulated. Interestingly, it has been suggested that
Tpr regulated the export of mRNAs,21 indicating a regulatory
role of Tpr in protein translation. Additionally, we can pinpoint
proteins that are regulated by the same upstream signals; for
example, in 4T1 cells, glyceraldehyde-3-phosphate dehydrogen-
ase, enolase-1, lactate dehydrogenase-A, phophoglycerate
Figure 5. Immunohistochemistry staining of a 4T1 FFPE tumor tissue section and MALDI-MSI analysis. (A) IHC staining of pimo localization
within a FFPE 4T1 pimo-treated tumor tissue section. Serial tissue sections were then subjected to MALDI-MSI analysis. (B) MALDI-mass
spectrum acquired from a FFPE 4T1 pimo-treated tumor tissue section. (C) MALDI-MS images of peptides within the tissue sections. The
localizations of galectin, ﬁbronectin, and phosphoglycerate kinase within pimo-treated tumor tissue sections indicate that hypoxic regions are
displayed. This was found to be in good agreement with the IHC staining of pimo within the tumor tissue sections. HBB and HBA are also shown to
indicate the presence of blood vessel in the tumor.
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kinase-1, and aldolase-A all neighbor triosphophate isomerase-1.
These are all glycolysis pathway proteins and are known to be
up-regulated in hypoxia.22 We can also use this tool to identify
potential protein−protein interactions within the system. For
example, RanBP2 neighbors Nup214; it has been previously
established that RanBP2 attaches to the nuclear pore complex via
association with Nup214.23
■ DISCUSSION
Hypoxia, which occurs in most solid tumors, is clinically
correlated with metastatic progression, treatment failure, and
decreased patient survival. Therefore, the identiﬁcation of
hypoxia-regulated proteins that drive metastasis as well as
understanding the molecular networks that are associated with
hypoxia could lead to the identiﬁcation of novel therapeutic
strategies.
In the study reported here, several approaches have been
combined to identify in vitro and in vivo protein changes in
normoxic versus hypoxic conditions. LC−MS/MS analysis of
SILAC-labeled breast cancer cells has allowed a relative
quantitative comparison of protein changes observed in both
normoxia and hypoxia. 131 proteins found to be hypoxia-
modulated were identiﬁed. However, the quantiﬁcation
methodology can be improved by using in-solution tryptic
digest as opposed to the in-gel digestion used in this study to
minimize potential keratin contamination and thus maximize
the sensitivity in protein detection/discovery.24 In addition, the
presence of Coomassie Blue in the SDS-PAGE gel may
interfere with digestion, again suggesting that in-solution
digestion may be a better option in studies such as ours.
MALDI-MSI is a fast growing technique with the ability to
localize proteins directly within tissue sections with no need for
predeﬁned targets. Hence, it is a powerful tool for translational
research strategies. Here the use of MALDI-MSI has allowed
the distribution of several proteins within breast tumor tissue
sections to be visualized as well as hypoxic and normoxic
regions to be distinguished. Such information can then be
correlated with histology and IHC studies to have greater
insight into the association between tumor morphology and
molecular biology. The distribution of these peptides as well as
their relative intensities across the tumor tissue sections were in
good agreement with the quantitative analysis. Importantly, the
statistical analysis of the selected MALDI-MSI detected
peptides with IHC staining revealed strong veriﬁcation of the
presence of these peptides in the hypoxic areas. These
techniques, when combined together, suggest the great
potential of MALDI-MSI to be used as a blind-search tool to
discover novel proteins associated with tissue microenviron-
ments. The direct identiﬁcation of proteins within tissue
sections has also been demonstrated in several studies.7b,9a,c
Here we used LCM to isolate the regions of interest within the
tumor tissue sections prior to LC−MS/MS analyses for protein
identiﬁcation. Using LCM prior to LC−MS/MS analysis
enabled the identiﬁcation of 118 and 164 proteins in situ in
the normoxic and hypoxic areas of the 4T1 tumor tissue
sections, respectively.
The combination of techniques used in this study, including
LC−MS/MS SILAC-labeled cell proteomics and LCM
LC−MS/MS on tumor tissue sections, allowed the identi-
ﬁcation and quantiﬁcation of a large number of proteins within
mammary tumors as well as distinguished hypoxic and
normoxic regions within the tumor environment. Combining
these technologies with MALDI-MSI brings speciﬁcity to the
methodology used here and also enables the localization of
several proteins within the tissue section, including low-
abundant proteins as well as targeted proteins, that is,
Figure 6. Distribution of peak intensities of phosphoglycerate kinase in normoxic (blue) and hypoxic (red) tissue. (A) Boxplots and (B) density
distributions of peptide intensities show that average expression of phosphoglycerate kinase is signiﬁcantly higher in hypoxic tissue compared with
normal tissue (Student’s t test, p value < 0.01). High variance of peptide intensities in both tissue types is likely due to the coarse grained acquisition
of MALDI MS spectra (80 μm), spanning multiple cells.
Table 3. Query Proteins Tested for Equal Mean of
Expression in Hypoxic and Normoxic Tissue, Respectivelya
protein matched peptide m/z t test [P value]
ﬁbronectin 1151.6 2.80 × 10−3
1169.7 4.80 × 10−9
galectin 1187.5 6.50 × 10−8
hemoglobin A 1529.7 2.20 × 10−3
hemoglobin B 1274.7 4.50 × 10−1
heat Shock protein 27 987.6098 5.10 × 10−19
phosphoglycerate kinase 1083.6044 1.30 × 10−35
aQuery proteins were in silico digested and the observed peptide
masses were compared to the theoretical values. Populations of peak
intensities from normoxic and hypoxic tissue were tested for equal
mean using a two sample Student’s t-test. All tested proteins, except
hemogolobin B, showed a signiﬁcant (p < 0.01) diﬀerence of mean
expression between both tissue types.
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hypoxia-related proteins. The combination of LCM-LC−MS/MS
with MALDI-MSI enabled the identiﬁcation and localization of
several proteins within the tumor tissue sections. Because no
separation step is performed prior to MALDI-MSI analysis, this
results more often in a crude mixture of peptides with other
biomolecular species including lipids, small molecules, as well as
protein modiﬁcations being present. Hence, on-tissue MALDI-
MS/MS analyses lead to poor results when compared with
conventional LC−MS/MS due to sample complexity. However,
as demonstrated here, using both data sets from LCM-LC−
MS/MS and MALDI-MSI allowed us, on one hand, to obtain
the proteomic information contained in the sample; on the
other hand, we were able to associate this information with the
spatial localization within the tissue section. This can be
visualized in Figure 4, which shows the combined results from
all analyses including SILAC LC−MS/MS, LCM-MS/MS, and
MALDI-MSI data. The discrepancies observed between these
in situ studies (i.e., LCM LC−MS/MS and MALDI-MSI) may
be explained by the diﬀerent preservation techniques of tumor
sections, as frozen tissues were used for LCM LC−MS/MS,
whereas we could only perform MALDI-MSI on FFPE-
preserved tissues successfully (data not shown). The freeze−
thawing of tumor sections may have caused degradation of
proteins. In addition, the use of a Denator system on the FFPE
tissue sections used for MALDI-MSI provided further
stabilization of proteins. Furthermore, in vitro and in vivo
environment can elicit diﬀerent responses in cancer cells; the
discrepancies between our in vitro SILAC results and in situ
LCM LC−MS/MS results highlight this issue.
Here MALDI-MSI analyses of on-tissue digested proteins
generated large data sets, which demonstrated diﬀerences
between peptide proﬁles when comparing hypoxic versus
normoxic regions, hence reﬂecting the complexity and
heterogeneity of the molecular nature of the disease. There is
thus a huge need for bioinformatic studies to create tools that
allow network building and results management. We have
achieved this in our study by developing a tool to visualize the
interaction network between in vitro MS-detected proteins.
The algorithm demonstrated here allowed for visualization of
large data sets without bias but still retained information that
might be important. The algorithm applied stringent ﬁlters for
identiﬁcation of the proteins but also presented identiﬁed
proteins whose expressions were not ‘signiﬁcantly’ changed
(i.e., 1.4 fold change in this study). This allowed a true view of
the network status of the various proteins at the time of sample
collection and may reveal a ‘hub’ of proteins that were
interconnected, which were signiﬁcantly changed in expression
by hypoxia. For example, the protein network highlighted in
Figure 7B is involved in the glycolytic pathway. This is not
surprising because hypoxia is known to induce a shift from the
Figure 7. Cytoscape visualization of in vitro protein network in 4T1 mammary cancer cells. Results from in vitro MS study on 4T1 hypoxic- and
normoxic-treated cells were run through algorithms to generate a view of the connections between MS-detected proteins. Red nodes denote proteins
signiﬁcantly up-regulated in hypoxia, blue nodes denote proteins signiﬁcantly down-regulated in hypoxia, and white nodes denote proteins with no
signiﬁcant changes between hypoxia and normoxia. Sizes of nodes correspond to degree of connection, and kinases were displayed as squares. (A)
Zoom-in of the major network with interconnected hubs is displayed. (B) Zoom-in of one of the individual subnetworks detected. Single-connection
proteins are also detected.
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normal oxidative phosphorylation that occurs in the mitochon-
dria to the so-called ‘anaerobic’ glycolysis due to the limited
amount of oxygen available to the cells. As such, these
glycolytic enzymes presented in the Cytoscape network may be
good therapeutic targets against hypoxia-mediated breast cancer
progression. In addition to revealing ‘hubs’, the algorithm also
presented proteins that may interact or regulate with the
signiﬁcantly regulated protein, as determined from the
STRING score. This presentation of protein networks allows
for identiﬁcation of new potential drug targets; for example, if a
protein identiﬁed is deemed ‘undruggable’ due to various
reasons, by looking at the connections around it using the
network, we could identify an interactor, upstream regulator or
downstream eﬀector to target instead. As such, the algorithm
demonstrated here can be of immense value for handling large
data sets.
HIF1α, arguably the most robust hypoxia-regulated protein,
was not present in the results here. However, this is not due to
the lack of robustness of our experimental approaches but
rather due to the transient nature of the protein. An alternative
approach to assessing hypoxia is the detection of more stable
known hypoxia-regulated proteins.
The detection of well-characterized hypoxia-regulated
proteins such as galectin-1,25 alpha-enolase,26 and 78 kDa
glucose-regulated protein (GRP78) 27 in the samples is
indicative of the robustness of our detection system. These
proteins were also detected in our in vitro SILAC system, which
further conﬁrms the validity of our study. In addition, further
well-known hypoxia-induced proteins such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, or G3P in mouse), L-lactate
dehydrogenase (LDHA), phosphoglycerate kinase 1 (PGK1),
aldolase A (ALDOA), and alpha-enolase (ENOA) were also
present in the list of signiﬁcantly hypoxia up-regulated proteins
in the in vitro SILAC studies, highlighting the robustness of our
hypoxic system.26,28
To date, there has been only one other study investigating an
in situ molecular proﬁle of the hypoxic tumor microenviron-
ment. Marotta and colleagues also used the LCM technique to
isolate hypoxic tissues, as we have done in this study, although
they focused on the mRNA levels as opposed to our
proteomics approach.29 Nevertheless, one could expect to see
some overlap between their mRNA proﬁle and our proteomics
proﬁle. Interestingly, none of the proteins encoded by the top
20 up/down-regulated mRNA changes observed by Marotta et
al. (2011) were detected in our in situ tumor sections. This
could be attributed to the fact that mRNA transcription does
not necessarily lead to translation and also to the diﬀerences in
cancer models and species that were used in the two studies:
Marotta et al. studied gliomas in rats, whereas we studied
mammary tumors in mice.
There appears to be more overlap between our individual in
vitro data sets (see the table in the Supporting Information)
and the mRNA data produced by Marotta and colleagues. This
could be due to the more homogeneous nature of in vitro
systems compared with in vivo systems. However, if we look at
the combined results from all three SILAC in vitro repeats,
Marotta et al. did not detect any of the proteins consistently
regulated by hypoxia in our study at the mRNA level. This is
likely due to the same reasons previously listed: the fact that
mRNA levels do not necessarily reﬂect protein dynamics, in
addition to the diﬀerences in cell lines and hypoxia treatments.
Additionally, the in-gel digestion for extraction of in vitro
SILAC samples may not have been completely eﬃcient across
the three experiments, and the overlap between the repeats may
be improved by other sample preparation methods, such as in-
solution digestion.
Table 4. List of in Vitro MS-Detected Proteins with Signiﬁcant Changes between Hypoxia and Normoxia with Neighbors of
Other Signiﬁcantly Altered Protein in 4T1 Mammary Cancer Cellsa
enquiry protein score neighbor 1 score 1 neighbor 2 score 2 neighbor 3 score 3 neighbor 4 score 4 neighbor 5 score 5
Nup214 down Ranbp2 down Tpr down
Vim down Krt18 down
Hspd1 down Hspa9 down
Krt18 down Vim down
Ranbp2 down Nup214 down Tpr down
Tpr down Nup214 down Ranbp2 down
Hspa9 down Hspd1 down
Vim down Tpm4 up
Eno3 down Pgam1 up Aldoa up
Tpm4 up Vim down
Aldoa up Eno3 down
Pgam1 up Eno3 down
Gapdh up Tpi1 up
Pfkl up Aldoa up
Ldha up Tpi1 up Aldoa up
Aldoa up Gapdh up Ldha up Pgam1 up Tpi1 up Pfkl up
Pgk1 up Gapdh up Pgam1 up Tpi1 up
Tpi1 up Eno1 up Gapdh up Ldha up Pgk1 up Aldoa up
Eno1 up Tpi1 up
Pgam1 up Pgk1 up Aldoa up
Gapdh up Pgk1 up Tpi1 up Aldoa up
aResults from in vitro MS study on 4T1 hypoxic- and normoxic-treated cells were run through algorithms to extrapolate signiﬁcantly changed
proteins that are neighbors with other signiﬁcantly altered protein(s). Proteins were scored ‘up’ or ‘down’, indicating ‘signiﬁcant down-regulation in
hypoxia’ and ‘signiﬁcant up-regulation in hypoxia’, respectively.
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Of the proteins that were identiﬁed in both in vitro SILAC
and in situ LCM mass spectrometry analyses, we have identiﬁed
a novel hypoxia-regulated protein tropomysin alpha-4 chain
(TPM4), which was found to be signiﬁcantly up-regulated
in vitro in hypoxic 4T1 cells and was also detected in the
hypoxic regions of the 4T1 tumor samples. TPM4 is involved in
regulating actin ﬁlaments of cells, and while there has been no
previous report suggesting a link between TPM4 and hypoxia,
previous immunohistochemical analysis on lymph node metastases
of breast cancer patients showed a signiﬁcant association of TPM4
with metastasis.30 Hypoxia is known to enhance metastasis;31 as
such, the hypoxia-induced TPM4 reported here may be involved
in modifying the actin cytoskeleton and mobilizing cancer cells to
metastasize. It would be interesting to validate this hypothesis by
knocking down TPM4 and observing the eﬀects on hypoxia-
induced invasion of 4T1 cells in a future study. Nonetheless, here
we have demonstrated that TPM4 may be a novel hypoxic marker
for breast cancer cells.
Interestingly, one of the most down-regulated proteins in the
in vitro hypoxic 4T1 cells was the histone H2B type 1 protein.
Family members of this H2B type 1 protein were also detected
in our in situ LCM samples, alongside with other histone
proteins (H3, H4). Similar to TPM4, there has been no study
linking the expression of H2B type 1 protein to hypoxia,
suggesting that this group of proteins may potentially be novel
hypoxic-regulated proteins. Histones are responsible for the
packaging and structural arrangement of DNA into chromatins
and undergo posttranslational modiﬁcations to alter their
interactions with DNA and nuclear proteins. These modiﬁcations
are also involved in regulating the chromatin structures and thus
transcriptional control of the DNA within (known as epigenetic
control). If histones were lost, then one could imagine the DNA
to become disorganized, and the control over transcription of
said DNA would be lost, thereby introducing genomic instability.
This presents a very interesting new mechanism to which
hypoxia may induce genomic instability.
■ CONCLUSIONS
We have reported here the ﬁrst comprehensive study on
hypoxia-regulated protein changes. We utilized several
MS-based approaches to identify hypoxia-regulated proteins in
mammary cancer cells in vitro and in situ and visualized these
proteins within tumor sections using MALDI-MSI. We further
provided a pipeline to which sections that underwent MALDI-
MSI could be directly compared with pimonidazole-stained IHC
sections and identiﬁed peptides that were signiﬁcantly localized
in hypoxic areas. This presents an exciting prospect that with
further optimization these techniques could provide a powerful
tool to identify speciﬁc proteins involved in the metastatic
process. We have also demonstrated the use of bioinformatics to
aid the analysis of an extensive proteomics network. The need to
develop bioinformatics tools can be highlighted by the complex
results generated by mass-spectrometry methods, as demon-
strated by our results here, wherein vitro and in situ results may
not be in concordance. A computational approach to bringing
the results together is essential in dealing with large data sets
generated by MS techniques.
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